ConclusionsIn the clinical setting, serological screening of children for CD is highly accurate.Currently, there is no evidence to support screening all children for CD. Screening of at-riskchildren looks attractive but needs further study. Standardization of screening tests, assessmentof appropriate cutoffs for screening, and algorithms for the evaluation of cases identified onscreening are needed.Areas for Further Study(1) Clarify the natural history of CD and TG seropositivity (to assess the benefit of earlyor preventive treatment) in general, and on type 1 diabetes outcome specifically. (2) Standardizedefinitions and algorithms for evaluation of screening-identified CD. (3) Identify methods topredict progression to frank disease; possible factors include gene dosage, diet, modifier genes,environmental factors, TG quantitation, etc. (5) Analyze the cost/benefit/harm in screening, theoptimal age to begin screening, and frequency of repeat screening. (6) Standardize methods forscreening (tests, cutoffs) children.References1. Frankenburg WK. Selection of diseases and tests in pediatric screening. Pediatrics.1974;54:612–616.2. Wilson JM, Jungner YG. Principles and practice of mass screening for disease. Bol OficinaSanit Panam. 1968;65:281–393.3. Hoffenberg EJ, MacKenzie T, Barriga KJ, et al. A prospective study of the incidence ofchildhood celiac disease. J Pediatr. 2003;143:308–314.4. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-riskgroups in the United States: A large multicenter study. Arch Intern Med. 2003;163:286–292.5. Revised criteria for diagnosis of coeliac disease. Report of Working Group of EuropeanSociety of Paediatric Gastroenterology and Nutrition. Arch Dis Child. 1990;65:909–911.6. Hill ID, Dirks M, Liptak G, et al. Guideline for the diagnosis and treatment of celiac diseasein children: recommendations of the North American Society for Pediatric Gastroenterology,Hepatology, and Nutrition. J Pediatr Gastroenterol Nutr. 2004;in press.7. Hoffenberg EJ, Bao F, Eisenbarth GS, et al. Transglutaminase antibodies in children with agenetic risk for celiac disease. J Pediatr. 2000;137:356–60.8. Maki M, Mustalahti K, Kokkonen J, et al. Prevalence of <strong>Celiac</strong> disease among children inFinland. N Engl J Med. 2003;348:2517–2524.9. Liu E, Bao F, Barriga K, et al. Fluctuating transglutaminase autoantibodies are related tohistologic features of celiac disease. Clin Gastroenterol Hepatol. 2003;1:356–362.81
10. Hoffenberg EJ, Emery LM, Barriga KG, et al. Clinical features of children with screeningidentifiedevidence of celiac disease. Pediatrics. 2004;113(5):1254–1259.11. Freemark M, Levitsky LL. Screening for celiac disease in children with type 1 diabetes: twoviews of the controversy. Diabetes Care. 2003;26:1932–1939.12. Fabiani E, Taccari LM, Ratsch IM, Di Giuseppe S, Coppa GV, Catassi C. Compliance withgluten-free diet in adolescents with screening-detected celiac disease: A 5-year follow-upstudy. J Pediatr. 2000;136:841–843.82
- Page 1 and 2:
NIH Consensus Development Conferenc
- Page 3 and 4:
III. What Are the Manifestations an
- Page 5 and 6:
• What is the management of celia
- Page 7 and 8:
Monday, June 28, 2004 (continued)I.
- Page 9 and 10:
Monday, June 28, 2004 (continued)II
- Page 11 and 12:
Wednesday, June 30, 2004 (continued
- Page 13 and 14:
Lisa H. RichardsonConsumer Represen
- Page 15 and 16:
Ciaran P. Kelly, M.D.Director, Celi
- Page 17 and 18:
Van S. Hubbard, M.D., Ph.D.Director
- Page 19 and 20:
AbstractsThe following are abstract
- Page 21 and 22: susceptibility (e.g., DR17 homozygo
- Page 23 and 24: The Pathology of Celiac DiseaseDavi
- Page 25 and 26: In this regard, the transport pathw
- Page 27 and 28: for the IgG-based test, while speci
- Page 29 and 30: 15. de Lecea A, Ribes-Koninckx C, P
- Page 31 and 32: Clinical Algorithm in Celiac Diseas
- Page 33 and 34: Considera diagnosisof celiac diseas
- Page 35 and 36: There are populations at particular
- Page 37 and 38: Serological Testing for Celiac Dise
- Page 39 and 40: Estimates of the sensitivity of the
- Page 41 and 42: the risk and severity of CD may als
- Page 43 and 44: What Are the Prevalence and Inciden
- Page 45 and 46: ascribed to excess menstrual loss.
- Page 47 and 48: ReferencesFamily History of Celiac
- Page 49 and 50: Carroccio A, Iannitto E, Cavataio F
- Page 51 and 52: identified by surveys or through so
- Page 53 and 54: Clinical Presentation of Celiac Dis
- Page 55 and 56: een widely reported. The question r
- Page 57 and 58: The Many Faces of Celiac Disease: C
- Page 59 and 60: References1. Green PH, Jabri B. Coe
- Page 61 and 62: Association of Celiac Disease and G
- Page 63 and 64: Does the Gluten-Free Diet Protect F
- Page 65 and 66: Skin Manifestations of Celiac Disea
- Page 67 and 68: allow a better understanding of the
- Page 69 and 70: 4. Henriksson KG, Hallert C, Walan
- Page 71: characterized, clinically-identifie
- Page 75 and 76: ataxia, epilepsy with posterior cer
- Page 77 and 78: Consequences of Testing for Celiac
- Page 79 and 80: Osteoporosis/FracturesThere were 11
- Page 81 and 82: Dietary Guidelines for Celiac Disea
- Page 85 and 86: 21. Thompson T. Thiamin, riboflavin
- Page 88 and 89: In order to effectively counsel ind
- Page 90 and 91: 9. Hallert C, Granno C, Hulten S, M
- Page 92 and 93: adhered to the GFD after more than
- Page 94 and 95: Patient education, close supervisio
- Page 96: 26. Mustalahti K, Lohiniemi S, Laip
Change language